Marinus Pharmaceuticals: Pipeline, Commercial Strategy Highlighted

Ainvest AIGCTue, Sep 19, 2023 ET

1min read

• Marinus Pharmaceuticals is advancing its pipeline and commercial strategy• RAISE trial enrollment trends have returned to anticipated levels• ZTALMY's commercial launch continues with estimated net product revenue of $5-5.2 million for Q3 2023• The company now expects a cash runway into Q4 2024 with projected cash of $170-175 million as of September 30, 2023.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.